University of Washington

Ethan Merritt

Dustin James Maly

Wesley C Van Voorhis

Kayode K Ojo

Eric T Larson

Wilhelmus G J Hol

Wilhelmus Gj Hol

Wilhelmus GJ Hol

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite() and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites() and() are described. In particular, the present disclosure is directed to compositions and methods for inhibiting eithercalcium dependent protein kinases (TgCDPKs) orandcalcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, 

Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases

The present disclosure is directed to compositions and methods for inhibiting either() calcium dependent protein kinases (TgCDPKs) or() and() calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R, and Rare defined herein.

Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases

Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite() and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites() and() are described. In particular, the present disclosure is directed to compositions and methods for inhibiting eithercalcium dependent protein kinases (TgCDPKs) orandcalcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R, and Rare defined herein.

The present disclosure is directed to compositions and methods for inhibiting either() calcium dependent protein kinases (TgCDPKs) or() and() calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-&#x3b1;]pyrazine inhibitors, of the Formula (I), wherein the variables X, Y, Z, R, and Rare defined herein.

Growing community of inventors

Seattle, WA, United States of America

Ethan Merritt